Restarting Apixaban After Intracranial Hemorrhage

Critical Decision Points

The American Heart Association/American Stroke Association (AHA/ASA) guidelines recommend avoiding long-term anticoagulation after lobar ICH in patients with nonvalvular atrial fibrillation due to the relatively high rebleeding risk 1, 2
Lobar hemorrhages carry the highest risk of recurrence and likely indicate underlying cerebral amyloid angiopathy, particularly in elderly patients 1, 2, 3
Decision analysis studies demonstrate that elderly patients with lobar ICH have much higher projected risk of poor outcomes if warfarin is continued, and this applies to DOACs as well 4
For lobar ICH patients, strongly consider antiplatelet monotherapy or left atrial appendage closure as safer alternatives to any anticoagulant 5

The AHA/ASA guidelines suggest restarting apixaban at 4-6 weeks after the hemorrhage for patients with atrial fibrillation and moderate stroke risk (CHADS₂ 2-3) 1, 2, 3
Restart apixaban at 7-10 days for patients with mechanical heart valves (especially mitral position), atrial fibrillation with CHADS₂ score ≥4, or recent VTE (within 3 months) 6, 7

Obtain repeat brain imaging (CT or MRI) to confirm hemorrhage stability and absence of expansion before restarting apixaban 7
Ensure adequate blood pressure control (target <130/80 mmHg long-term) before restarting apixaban 1
Document absence of new microbleeds if MRI available before restarting apixaban 2

The AHA/ASA guidelines state that the usefulness of apixaban in patients with atrial fibrillation and past ICH to decrease the risk of recurrence is uncertain (Class IIb, Level of Evidence C) 1, 2, 3
Apixaban has practical advantages over warfarin, including lower ICH risk in primary prevention trials and no need for INR monitoring 2, 7

Aspirin monotherapy appears generally safe after ICH, including in cerebral amyloid angiopathy (CAA) patients 5
Percutaneous left atrial appendage closure is a viable alternative for atrial fibrillation patients who cannot restart anticoagulation 5

Mechanical heart valves carry thromboembolism rates of at least 4% per year off anticoagulation, justifying earlier restart at 7-10 days after confirming hemorrhage stability, as recommended by the American Heart Association 8, 9
Atrial fibrillation with CHADS₂ ≥4 or prior ischemic stroke warrants restart at 7-10 days, according to the American College of Cardiology 9
Limited retrospective data showed only 0.8% rebleeding rate when anticoagulation was restarted at 7-10 days, versus 5% thromboembolism rate when held, as reported in the journal Circulation 9
Microbleeds on gradient echo MRI predict 9.3% ICH risk on anticoagulation versus 1.3% without, indicating extreme caution, as noted in the journal Stroke 8
Failure to reverse warfarin and achieve normal INR has been associated with increased rebleeding risk, as stated by the American Stroke Association 8
Failure to achieve therapeutic aPTT with heparin has been associated with increased ischemic stroke risk, according to the American Heart Association 8

Aspirin monotherapy appears generally safe after ICH, including in cerebral amyloid angiopathy patients, and can be restarted beyond 24 hours after ICH symptom onset, as suggested by the journal Stroke 10